NCI is developing patient-derived xenograft mouse models as a potential substitute for the NCI-60 cell lines, a standard screen which experts say can no longer keep up with advances in cancer research and targeted molecular therapy.
President Barack Obama's Feb. 8 budget request for fiscal year 2017 slates $75 million in additional funding for FDA for the creation of a virtual Oncology Center of Excellence.
Devices aren't tracked with the same rigor as drugs, because FDA does not have a data system that can reliably track medical devices and identify potential safety problems, according to Gregory Daniel, fellow and managing director of the Center for Health Policy at Brookings Institution.
Patients are being harmed because FDA doesn't commit sufficient resources to enforce federal requirements for hospitals and manufacturers to report adverse outcomes caused by medical devices, according to Larry Pilot, one of the original authors of FDA's 510(k) device clearance process.
FDA's Class II 510(k) clearance process for medium-risk devices—a category that includes the power morcellator—is inadequate, because it does not focus on risk assessment, according to Bill Vodra, a former associate chief counsel for drugs at FDA.
Lilly Oncology has launched a novel value assessment tool that aggregates 40 years of oncology data to measure progress and identify unmet needs in cancer treatments.
The Cancer Letter invited Richard Wender, chief cancer control officer of the American Cancer Society, to describe the rationale for the society’s new guideline for breast cancer screening.
After a decade of near-absence from the US market, the AstraZeneca drug Iressa (gefitinib) is back.
Here is what Hagop Kantarjian has learned over the past two years of his campaign to lower the prices of cancer drugs:People would rather avoid disputing you head-on.
The NCI-MATCH phase II study is intended to allow the institute and its clinical trials groups catapult to the premier role in cancer research.
